The tumor microenvironment plays a key role in the anatomical changes, molecular alterations and pathway derangements that prop up the deregulation of physiological processes leading to the onset and clinical progression of neoplastic disease, but at the same time it could be addressed for cancer treatment [1, 2] . In particular, the development of appropriate vasculature is necessary to supply nutrients and oxygen to tumor tissue: the generation of newly formed vessels from pre-existing blood vessels is defined as neoangiogenesis and is crucial for tumor expansion. Tumors with a volume smaller than 0.2 cm are composed of roughly one million cells, are nourished by substances delivered by capillaries of the host tissue, and exploit metabolites and oligoelements present in the extracellular fluid. Larger tumors need the formation of new capillary blood vessels, and neoplastic tissue induces the existing host capillaries to bud, swing and develop throughout the tumor. Tumor vessels are dissimilar with respect to normal vessels and may afford a site of entrance for metastasis, and their endothelial cells may provide valuable targets for therapeutic approaches [3, 4] . Malignancy is related to metastatic progression, which is the principle cause of cancer-related death, and the liaison between tumor and host tissue, as well as the interaction between cancer cells and the niche created by the microenvironment comprising the tumour-associated stroma, directs the evolution of malignant neoplasms from the beginning to metastatic spreading [5] . The process of neoangiogenesis is controlled by growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), which are produced through autocrine or paracrine secretion by components of the tumor microenvironment and exert their effects on neighbouring cells [6] . An important interplay has been evidenced between VEGF and transcription factors of the peroxisome proliferatoractivated receptor (PPAR) family. Specifically, PPARd/b plays a role in carcinogenesis and influences oncogenic signalling, and modulation of this nuclear receptor by means of inhibitory ligands has been proved to hinder invasiveness [7] . In this perspective, the interesting findings reported by J. Zhou and L. Yang and co-authors shed new light on the role of PPARd/b in colorectal carcinogenesis. As evidenced by this group, there was differing expression and sub-cellular localization of this transcription factor in the endothelial cells of vascular structures in tumor tissue with respect to normal mucosa, and this different pattern seemed to influence patient survival [8] . In particular, the increased frequency of a lower expression of PPARd/b in the endothelial cells of the neoplastic tissue was mostly accompanied by cytoplasmic localization, as evidenced by immunohistochemical assay, and was associated with increased expression of angiogenesis-related genes, such as VEGF for vascular endothelium and D2-40 for lymphatic endothelium. It was also correlated with better cellular differentiation, less advanced disease stage, and more favourable overall patient survival. On the other hand, a poorer survival was evidenced in colorectal cancer patients characterized by low expression levels of PPARd/ b in tumor cells, suggesting that in the context of colorectal malignant neoplasms, the same transcription factor may behave as a tumor suppressor if highly expressed in tumor tissue, or as an oncogene if highly expressed in the vasculature of tumor-associated stroma. These data further corroborate the mounting evidence that the microenvironment surrounding and supporting the neoplastic cells can influence the malignancy of an emergent cancer and foster metastatic spreading [9, 10] . The several components of the tumor stroma play different functions, interplaying in a complex way, and they can hard-wire a multifaceted system that crucially determines cancer behaviour and disease outcome, but at the same time they must be regarded as strategic therapeutic targets.
